Guangzhou, China and Woodland Hills, USA: Angitia Biopharmaceuticals is delighted to announce the appointment of Mr. David A Piacquad as an Independent Board Director.
Mr. Piacquad is an executive with nearly 40 years of experience in the biopharmaceutical and health care industries. Until 2022, Mr. Piacquad was the Senior Vice President of Business Development and an executive officer at Amgen. During his tenure, Mr. Piacquad completed acquisitions and collaborations that significantly expanded Amgen's revenue, pipeline, and international footprint. Prior to this role, Mr. Piacquad served as vice president, Strategy & Corporate Development, responsible for mergers and acquisitions, inbound and outbound licensing, Amgen Ventures and corporate alliance management. Prior to Amgen, Mr. Piacquad was senior vice president, Business Development & Licensing at Schering-Plough Corporation. Before joining Schering-Plough, Mr. Piacquad had spent more than 20 years at Johnson & Johnson.
Mr. Piacquad holds a BA degree from Colgate University and an MBA from the Wharton School at the University of Pennsylvania.
Dr. David Ke, Board Chairman and CEO of Angitia, said of the appointment “Dave’s extensive experience in leading business development and strategy initiatives, and executing transactions in the biopharmaceutical industry brings great strength to the Angitia board. I am delighted to see him join the board and help drive the company forward. Dave’s expertise in drug R&D and business development will be extremely valuable to Angita’s next phase of growth.”
Mr. Piacquad comments “I am very pleased to have the opportunity to join Angitia’s excellent board and contribute to Angitia’s mission of discovery, development and commercialization of breakthrough therapeutics that address large unmet medical needs of patients with serious musculoskeletal diseases. With an aging society, the demands for innovative treatments for serious musculoskeletal diseases have been rapidly increasing in recent decades and this trend will continue for the foreseeable future. Since its establishment, Angitia has assembled an excellent team of drug hunters and drug developers with a great deal of experience and a successful track record in this area. This has enabled Angitia to quickly generate a very innovative R&D drug pipeline. I believe Angitia’s promising pipeline will bring great value to patients in need”.
Angitia is a clinical-stage biotechnology company focused on the discovery and development of breakthrough therapeutics that address the key unmet medical needs of serious musculoskeletal diseases. With the team's experience and scientific expertise in new drug discovery and development, Angitia is dedicated to bringing innovative therapies to help patients in need.
Founded in 2018, Angitia is now with operation sites in Guangzhou, Guangdong, China and Woodland Hills, California, USA.